Biopharmaceutical group Hemogenyx Pharmaceuticals said it had entered into a research agreement with the University of Pennsylvania to accelerate the development of its potential acute myeloid leukemia treatment. The agreement was envisaged as the first step of a larger program that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of acute myeloid leukemia, the company said. 'We are confident that this collaboration will dramatically accelerate the development of our CAR-T product candidate, which we believe will have a significant and positive impact in the treatment of acute myeloid leukemia, for which there is currently no real effective treatment,' it added At 10:08am: (LON:HEMO) Hemogenyx Pharmaceuticals Plc share price was +0.24p at 9.2p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.